American donors put faith (and dollars) in TAU cance...(least of which is the genetic predisposi...),Health

The 1995 discovery was hailed by the prestigious American journal Science as the medical equivalent of the Rosetta Stone in deciphering the biochemical mysteries of cancer. Since then, Prof. Shiloh's lab has made several seminal discoveries about the function of the A-T gene, especially in its role in defending the living cell from the consequences of radiation damage. This research has paved the way for a more accurate diagnosis of the disease in patients around the world and has led to new directions in the search for potentially effective treatments.

Prof. Shilohs research is phenomenal, remarks Leah Susskind, an ICRF chairperson emeritus from New York. He is just out of this world. Listening to him explaining his research made my heart tick. I should add that we find only the top, top scientists to benefit from our fund, and Prof. Shiloh from Tel Aviv University is definitely one of them.

Although most of the donors to the ICRF prefer to remain anonymous, Susskind says that those who are pouring dollars into Israeli research are not just Jewish supporters of Israel. An unusual number of Christian North Americans, some of whom have benefited from Israeli-developed cancer therapies directly, are also keen on giving to the fund.

Israeli research teams have developed some of the most important cancer therapies used by Americans today. The most well-known examples include Doxil, for breast and ovarian cancer; Gleevec, used against leukemia; the key tumor suppressor p53; and Velcade, for the treatment of multiple myeloma. But Israel isnt the only thing these treatments have in common -- they were all funded during some part of their development cycle by the ICRF.

Concludes Prof. Shiloh, All of us at Israeli universities feel the enormous contribution the ICRF has made to cancer research here. Since 1975, it has distributed no less than $35 million in grants to Israeli
'/>"/>